Barclays Lowers Procter & Gamble Price Target to $151 from $153, Keeps Equalweight Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy PG?
Source: Yahoo Finance
- Company Overview: Procter & Gamble Company (PG) has received an average rating of "overweight" from analysts.
- Price Target: The mean price target for PG is set at $169.71.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PG
Wall Street analysts forecast PG stock price to rise
17 Analyst Rating
10 Buy
7 Hold
0 Sell
Moderate Buy
Current: 156.860
Low
150.00
Averages
164.50
High
180.00
Current: 156.860
Low
150.00
Averages
164.50
High
180.00
About PG
The Procter & Gamble Company is focused on providing branded consumer packaged goods to consumers across the world. The Company’s segments include Beauty, Grooming, Health Care, Fabric & Home Care and Baby, Feminine & Family Care. The Company’s products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-commerce, including social commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. It also sells direct to individual consumers. It has operations in approximately 70 countries. It offers products under brands, such as Head & Shoulders, Herbal Essences, Pantene, Rejoice, Olay, Old Spice, Safeguard, Secret, SK-II, Braun, Gillette, Venus, Crest, Oral-B, Ariel, Downy, Gain, Tide, Always, Always Discreet, Tampax, Bounty and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investors Shift to High Dividend Stocks to Mitigate AI Risks
- Dividend Stocks Outperform: Investor Jenny Harrington notes that dividend-paying stocks have excelled this year, with the iShares Select Dividend ETF up nearly 11% year-to-date, contrasting with the S&P 500's flat performance, indicating a shift in investor preference towards traditional economy stocks.
- Market Rebalancing Trend: Harrington highlights that investors are recognizing the “irrationally wide” performance and valuation gaps between big tech and old economy stocks, prompting a portfolio rebalancing to mitigate uncertainties posed by artificial intelligence disruptions.
- Quality Dividend Stock Picks: Harrington recommends Kimberly-Clark, which has gained over 7% year-to-date and offers a 4.66% dividend yield, emphasizing its 92 years of dividend payments and 54 years of increases, showcasing its stable financial performance and growth potential.
- Attractive REIT Investment: Vici Properties, a REIT leasing to Las Vegas casinos, offers a 6.06% dividend yield, with tenants experienced in navigating economic downturns, suggesting continued growth and dividend increases in the future.
See More
Supreme Court Set to Rule on Tariff Authority
- Tariff Legality Review: The Supreme Court is poised to rule on the legality of tariffs imposed by President Trump under the International Emergency Economic Powers Act (IEEPA), which could significantly impact pricing and margin strategies for consumer giants like Costco and Procter & Gamble.
- Potential EBITDA Uplift: Morgan Stanley's analysis suggests that a rollback or limitation of IEEPA-based tariffs could lead to a mid-single-digit uplift in EBITDA for affected retailers, providing notable margin support amid economic pressures.
- Retailer Response Strategies: While awaiting the ruling, retailers such as Costco and Amazon are leveraging strong negotiating power and value-oriented business models to navigate tariff pressures, ensuring they protect consumer value even as costs rise.
- Optimistic Market Outlook: Despite tariffs remaining a defining feature of the trade landscape, analysts believe that consumer spending may receive additional support from tax refunds, making the retail and consumer staples sectors attractive investment opportunities.
See More
Analysis of Shiba Inu Investment Prospects
- Price Volatility Analysis: As of February 16, Shiba Inu (SHIB) has surged an astonishing 97,000% over the past five years, yet it currently trades 93% below its peak from October 2021, indicating significant price volatility and uncertainty.
- Market Potential Assessment: Should Shiba Inu's market cap increase by a factor of 100, it would reach $380 billion, comparable to valuations of notable companies like Home Depot, Bank of America, and Procter & Gamble; however, the likelihood of achieving this is extremely low.
- Lack of Utility: Despite having a metaverse, decentralized exchange, and Layer-2 scaling solutions, Shiba Inu's lack of real-world applications puts it at a disadvantage in attracting users compared to cryptocurrencies with deeper developer networks.
- Diminishing Community Enthusiasm: The significant drop in Shiba Inu's price from its historical peak reflects a waning community enthusiasm, suggesting that investors should approach this asset, which relies on unpredictable hype cycles, with caution.
See More
Shiba Inu Faces Declining Community Support
- Declining Community Support: Shiba Inu's price has plummeted 93% from its October 2021 peak, indicating a waning community support that could lead to decreased investor confidence and negatively impact its future market performance.
- Limited Investment Return Potential: Despite a staggering 97,000% increase over the past five years, analysts believe the future investment return potential for Shiba Inu is extremely low due to a lack of real-world applications and increasing competition, prompting investors to consider safer options.
- Intensifying Market Competition: As more cryptocurrencies with practical applications emerge, Shiba Inu faces fierce competition from other digital assets, which could further erode its market share and affect its long-term growth potential.
- Poor Investment Recommendation: Analysts have noted that Shiba Inu is not included in the current top ten recommended stocks, suggesting a diminishing appeal as an investment choice, and advising investors to consider more promising assets for long-term gains.
See More
Nestlé Reports Strong Q4 Sales Growth, Plans Divestitures
- Sales Growth Exceeds Expectations: Nestlé's organic sales growth rate for Q4 reached 4%, surpassing analyst expectations of 3.55%, indicating strong market performance that boosts investor confidence.
- Future Growth Targets: The company aims for organic sales growth of 3% to 4% in 2026 while planning to improve its underlying trading operating profit margin, which stood at 16.1% in 2025, reflecting a positive outlook for future performance.
- Business Restructuring Plans: Nestlé intends to sell its remaining ice cream business to Froneri and has initiated the process to divest its water business, expected to be completed by 2027, which will help streamline operations and focus on core brands.
- Management Strategy Shift: Under the leadership of new CEO Philipp Navratil and Chairman Pablo Isla, Nestlé is accelerating its strategic transformation by concentrating on four core businesses, aiming to enhance operational efficiency and market performance.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Investors Shift to High Dividend Stocks to Mitigate AI Risks
- Dividend Stocks Outperform: Investor Jenny Harrington notes that dividend-paying stocks have excelled this year, with the iShares Select Dividend ETF up nearly 11% year-to-date, contrasting with the S&P 500's flat performance, indicating a shift in investor preference towards traditional economy stocks.
- Market Rebalancing Trend: Harrington highlights that investors are recognizing the “irrationally wide” performance and valuation gaps between big tech and old economy stocks, prompting a portfolio rebalancing to mitigate uncertainties posed by artificial intelligence disruptions.
- Quality Dividend Stock Picks: Harrington recommends Kimberly-Clark, which has gained over 7% year-to-date and offers a 4.66% dividend yield, emphasizing its 92 years of dividend payments and 54 years of increases, showcasing its stable financial performance and growth potential.
- Attractive REIT Investment: Vici Properties, a REIT leasing to Las Vegas casinos, offers a 6.06% dividend yield, with tenants experienced in navigating economic downturns, suggesting continued growth and dividend increases in the future.
See More
Supreme Court Set to Rule on Tariff Authority
- Tariff Legality Review: The Supreme Court is poised to rule on the legality of tariffs imposed by President Trump under the International Emergency Economic Powers Act (IEEPA), which could significantly impact pricing and margin strategies for consumer giants like Costco and Procter & Gamble.
- Potential EBITDA Uplift: Morgan Stanley's analysis suggests that a rollback or limitation of IEEPA-based tariffs could lead to a mid-single-digit uplift in EBITDA for affected retailers, providing notable margin support amid economic pressures.
- Retailer Response Strategies: While awaiting the ruling, retailers such as Costco and Amazon are leveraging strong negotiating power and value-oriented business models to navigate tariff pressures, ensuring they protect consumer value even as costs rise.
- Optimistic Market Outlook: Despite tariffs remaining a defining feature of the trade landscape, analysts believe that consumer spending may receive additional support from tax refunds, making the retail and consumer staples sectors attractive investment opportunities.
See More
Analysis of Shiba Inu Investment Prospects
- Price Volatility Analysis: As of February 16, Shiba Inu (SHIB) has surged an astonishing 97,000% over the past five years, yet it currently trades 93% below its peak from October 2021, indicating significant price volatility and uncertainty.
- Market Potential Assessment: Should Shiba Inu's market cap increase by a factor of 100, it would reach $380 billion, comparable to valuations of notable companies like Home Depot, Bank of America, and Procter & Gamble; however, the likelihood of achieving this is extremely low.
- Lack of Utility: Despite having a metaverse, decentralized exchange, and Layer-2 scaling solutions, Shiba Inu's lack of real-world applications puts it at a disadvantage in attracting users compared to cryptocurrencies with deeper developer networks.
- Diminishing Community Enthusiasm: The significant drop in Shiba Inu's price from its historical peak reflects a waning community enthusiasm, suggesting that investors should approach this asset, which relies on unpredictable hype cycles, with caution.
See More
Shiba Inu Faces Declining Community Support
- Declining Community Support: Shiba Inu's price has plummeted 93% from its October 2021 peak, indicating a waning community support that could lead to decreased investor confidence and negatively impact its future market performance.
- Limited Investment Return Potential: Despite a staggering 97,000% increase over the past five years, analysts believe the future investment return potential for Shiba Inu is extremely low due to a lack of real-world applications and increasing competition, prompting investors to consider safer options.
- Intensifying Market Competition: As more cryptocurrencies with practical applications emerge, Shiba Inu faces fierce competition from other digital assets, which could further erode its market share and affect its long-term growth potential.
- Poor Investment Recommendation: Analysts have noted that Shiba Inu is not included in the current top ten recommended stocks, suggesting a diminishing appeal as an investment choice, and advising investors to consider more promising assets for long-term gains.
See More
Nestlé Reports Strong Q4 Sales Growth, Plans Divestitures
- Sales Growth Exceeds Expectations: Nestlé's organic sales growth rate for Q4 reached 4%, surpassing analyst expectations of 3.55%, indicating strong market performance that boosts investor confidence.
- Future Growth Targets: The company aims for organic sales growth of 3% to 4% in 2026 while planning to improve its underlying trading operating profit margin, which stood at 16.1% in 2025, reflecting a positive outlook for future performance.
- Business Restructuring Plans: Nestlé intends to sell its remaining ice cream business to Froneri and has initiated the process to divest its water business, expected to be completed by 2027, which will help streamline operations and focus on core brands.
- Management Strategy Shift: Under the leadership of new CEO Philipp Navratil and Chairman Pablo Isla, Nestlé is accelerating its strategic transformation by concentrating on four core businesses, aiming to enhance operational efficiency and market performance.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
